10 research outputs found

    High-efficiency Bragg grating enhanced on-chip photon-number-resolving detectors

    No full text
    The recent trend towards integration of quantum optics experiments has produced a demand for on-chip single photon detectors with high quantum efficiencies. In previous work we demonstrated integrated photon number resolving detectors for use at telecommunications wavelengths [1], here we outline developments of this design which have enabled improvements in the quantum efficiency, permitting an on-chip detection efficiency of 92% to be obtained in the device of Fig. 1. ..

    Integrated optical platform for photon-number resolving telecom-band detectors for photonic information processing

    No full text
    We report the development of the optical substrates for the demonstration of an integrated photon-number-resolving detector, operating in the telecom band at 1550 nm, employing an evanescently coupled design that allows it to be placed at arbitrary locations within a planar circuit. Up to five photons are resolved in the guided optical mode via absorption from the evanescent field into a tungsten transition-edge sensor. The detection efficiency is 7.2 ± 0.5%. The polarization sensitivity of the detector is also demonstrated

    Clinical and Molecular Phenotype of Aicardi-Goutières Syndrome

    Get PDF
    Aicardi-Goutières syndrome (AGS) is a genetic encephalopathy whose clinical features mimic those of acquired in utero viral infection. AGS exhibits locus heterogeneity, with mutations identified in genes encoding the 3′→5′ exonuclease TREX1 and the three subunits of the RNASEH2 endonuclease complex. To define the molecular spectrum of AGS, we performed mutation screening in patients, from 127 pedigrees, with a clinical diagnosis of the disease. Biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNASEH2C were observed in 31, 3, 47, and 18 families, respectively. In five families, we identified an RNASEH2A or RNASEH2B mutation on one allele only. In one child, the disease occurred because of a de novo heterozygous TREX1 mutation. In 22 families, no mutations were found. Null mutations were common in TREX1, although a specific missense mutation was observed frequently in patients from northern Europe. Almost all mutations in RNASEH2A, RNASEH2B, and RNASEH2C were missense. We identified an RNASEH2C founder mutation in 13 Pakistani families. We also collected clinical data from 123 mutation-positive patients. Two clinical presentations could be delineated: an early-onset neonatal form, highly reminiscent of congenital infection seen particularly with TREX1 mutations, and a later-onset presentation, sometimes occurring after several months of normal development and occasionally associated with remarkably preserved neurological function, most frequently due to RNASEH2B mutations. Mortality was correlated with genotype; 34.3% of patients with TREX1, RNASEH2A, and RNASEH2C mutations versus 8.0% RNASEH2B mutation–positive patients were known to have died (P=.001). Our analysis defines the phenotypic spectrum of AGS and suggests a coherent mutation-screening strategy in this heterogeneous disorder. Additionally, our data indicate that at least one further AGS-causing gene remains to be identified

    References

    No full text

    Diabetic Cognitive Dysfunction: From Bench to Clinic

    No full text

    List of Chemical Substances

    No full text
    corecore